Brief: OncoQuest Retains Services Of IQVIA To Manage Phase 3 Study In Frontline Ovarian Cancer

Quest PharmaTech

25/01/2019 23:22

Jan 25 (Reuters) - IQVIA Holdings Inc  IQV.N :
    * QUEST PHARMATECH - UNIT RETAINED SERVICES OF IQVIA TO
MANAGE
UNIT'S PLANNED PHASE 3 CLINICAL STUDY IN FRONTLINE OVARIAN
CANCER WITH OREGOVOMAB

Source text for Eikon:  ID:nCNW0YyHQa 
Further company coverage:  IQV.N 

 ((Reuters.Briefs@thomsonreuters.com;;))